Pliant Therapeutics, Inc.
General ticker "PLRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $87.5M (TTM average)
Pliant Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -10.1%.
Estimated limits based on current volatility of 2.5%: low 1.17$, high 1.23$
Factors to consider:
- Total employees count: 171 (+8.2%) as of 2024
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Product liability, Acquisition/divestiture risks, Data protection
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.24$, 4.12$]
- 2026-12-31 to 2027-12-31 estimated range: [1.15$, 3.72$]
Financial Metrics affecting the PLRX estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 179.22 > -0.60
- Positive: Shareholder equity ratio, % of 80.45 > 64.29
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PLRX quotes
Long-term PLRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.58MM | $0.00MM | $0.00MM |
| Operating Expenses | $185.72MM | $228.37MM | $150.07MM |
| Operating Income | $-184.15MM | $-228.37MM | $-150.07MM |
| Non-Operating Income | $22.81MM | $18.06MM | $0.73MM |
| Interest Expense | $1.27MM | $3.02MM | $2.56MM |
| R&D Expense | $127.80MM | $169.31MM | $109.16MM |
| Income(Loss) | $-161.34MM | $-210.30MM | $-149.34MM |
| Net Income(Loss)* | $-161.34MM | $-210.30MM | $-149.34MM |
| Stockholders Equity | $473.58MM | $304.08MM | $181.21MM |
| Assets | $512.15MM | $396.95MM | $225.23MM |
| Operating Cash Flow | $-116.36MM | $-155.50MM | $-128.34MM |
| Capital expenditure | $0.92MM | $3.85MM | $0.37MM |
| Investing Cash Flow | $-127.01MM | $140.34MM | $134.29MM |
| Financing Cash Flow | $274.40MM | $23.12MM | $-31.70MM |
| Earnings Per Share** | $-2.75 | $-3.47 | $-2.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.